Harrow (HROW) Competitors $38.69 -0.76 (-1.93%) As of 01:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HROW vs. TGTX, MRUS, CRSP, PTCT, KRYS, PCVX, ACAD, ACLX, ADMA, and ARWRShould you be buying Harrow stock or one of its competitors? The main competitors of Harrow include TG Therapeutics (TGTX), Merus (MRUS), CRISPR Therapeutics (CRSP), PTC Therapeutics (PTCT), Krystal Biotech (KRYS), Vaxcyte (PCVX), ACADIA Pharmaceuticals (ACAD), Arcellx (ACLX), ADMA Biologics (ADMA), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry. Harrow vs. Its Competitors TG Therapeutics Merus CRISPR Therapeutics PTC Therapeutics Krystal Biotech Vaxcyte ACADIA Pharmaceuticals Arcellx ADMA Biologics Arrowhead Pharmaceuticals Harrow (NASDAQ:HROW) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership. Is HROW or TGTX more profitable? TG Therapeutics has a net margin of 13.31% compared to Harrow's net margin of -4.49%. TG Therapeutics' return on equity of 26.05% beat Harrow's return on equity.Company Net Margins Return on Equity Return on Assets Harrow-4.49% -2.18% -0.35% TG Therapeutics 13.31%26.05%9.58% Do institutionals & insiders have more ownership in HROW or TGTX? 72.8% of Harrow shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 15.2% of Harrow shares are held by company insiders. Comparatively, 10.6% of TG Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk & volatility, HROW or TGTX? Harrow has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500. Which has higher earnings and valuation, HROW or TGTX? TG Therapeutics has higher revenue and earnings than Harrow. Harrow is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHarrow$199.61M7.17-$17.48M-$0.25-154.76TG Therapeutics$329M15.44$23.38M$0.3786.50 Do analysts prefer HROW or TGTX? Harrow presently has a consensus target price of $64.67, suggesting a potential upside of 67.14%. TG Therapeutics has a consensus target price of $46.25, suggesting a potential upside of 44.51%. Given Harrow's stronger consensus rating and higher probable upside, equities analysts plainly believe Harrow is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Harrow 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the media prefer HROW or TGTX? In the previous week, Harrow had 12 more articles in the media than TG Therapeutics. MarketBeat recorded 19 mentions for Harrow and 7 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 1.11 beat Harrow's score of 0.69 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 5 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryTG Therapeutics beats Harrow on 10 of the 17 factors compared between the two stocks. Get Harrow News Delivered to You Automatically Sign up to receive the latest news and ratings for HROW and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HROW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HROW vs. The Competition Export to ExcelMetricHarrowMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.43B$2.84B$5.80B$10.16BDividend YieldN/A56.65%5.69%4.61%P/E Ratio-154.4023.4374.6226.00Price / Sales7.17548.43468.1791.50Price / Cash284.26169.2537.0859.91Price / Book19.845.3512.156.30Net Income-$17.48M$32.95M$3.28B$270.75M7 Day Performance4.60%1.58%1.13%3.33%1 Month Performance11.08%8.84%7.44%6.49%1 Year Performance-8.03%0.76%63.14%28.08% Harrow Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HROWHarrow3.0835 of 5 stars$38.69-1.9%$64.67+67.1%-4.6%$1.43B$199.61M-154.40180Analyst RevisionTGTXTG Therapeutics4.1683 of 5 stars$32.38+0.5%$46.25+42.8%+40.7%$5.11B$329M87.51290Positive NewsMRUSMerus2.9344 of 5 stars$67.19-0.4%$88.75+32.1%+38.8%$5.10B$36.13M-12.2237Positive NewsCRSPCRISPR Therapeutics3.3026 of 5 stars$54.10-1.4%$71.60+32.3%+23.0%$4.99B$37.31M-9.96460Positive NewsPTCTPTC Therapeutics3.6468 of 5 stars$56.95-0.5%$69.00+21.2%+88.9%$4.55B$806.78M8.171,410Insider TradeKRYSKrystal Biotech4.9344 of 5 stars$145.20-3.4%$210.38+44.9%-27.4%$4.35B$290.52M29.51210Positive NewsPCVXVaxcyte2.2818 of 5 stars$32.41-1.8%$130.00+301.1%-70.9%$4.29BN/A0.00160News CoveragePositive NewsAnalyst ForecastACADACADIA Pharmaceuticals4.3958 of 5 stars$25.39+0.5%$28.88+13.7%+51.7%$4.26B$957.80M19.09510Positive NewsAnalyst ForecastACLXArcellx2.226 of 5 stars$71.11-2.1%$114.31+60.7%+4.4%$4.03B$107.94M0.0080Positive NewsADMAADMA Biologics3.7221 of 5 stars$16.42-2.7%$27.67+68.5%-4.7%$4.03B$426.45M19.09530Positive NewsARWRArrowhead Pharmaceuticals4.1574 of 5 stars$27.17-6.6%$43.14+58.8%+41.9%$4.02B$3.55M-21.23400Analyst Revision Related Companies and Tools Related Companies TG Therapeutics Alternatives Merus Alternatives CRISPR Therapeutics Alternatives PTC Therapeutics Alternatives Krystal Biotech Alternatives Vaxcyte Alternatives ACADIA Pharmaceuticals Alternatives Arcellx Alternatives ADMA Biologics Alternatives Arrowhead Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HROW) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harrow With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HROW Stock Alerts